Kairos Pharma, Ltd. Statistics
Kairos Pharma, Ltd. (KAPA) Stock Statistics & Valuation Metrics
Total Valuation
Kairos Pharma, Ltd. has a market cap or net worth of $1.54M. The enterprise value is $6.11T.
- Market Cap
- $1.54M
- Enterprise Value
- $6.11T
Share Statistics
Kairos Pharma, Ltd. has 3,385,383 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 3,385,383
- Owned by Insiders
- 32.08%
- Owned by Institutions
- 1.55%
Financial Efficiency
Kairos Pharma, Ltd.’s return on equity (ROE) is -0.86 and return on invested capital (ROIC) is -87.87%.
- Return on Equity (ROE)
- -0.86
- Return on Assets (ROA)
- -0.83
- Return on Invested Capital (ROIC)
- -87.87%
- Return on Capital Employed (ROCE)
- -0.88
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.36M
- Employee Count
- 4
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Kairos Pharma, Ltd. is -0.22. Kairos Pharma, Ltd.’s PEG ratio is -0.07.
- PE Ratio
- -0.22
- PS Ratio
- 0.00
- PB Ratio
- 0.39
- Price to FCF
- -0.37
- Price to Operating Cash Flow
- -0.37
- PEG Ratio
- -0.07
Income Statement
In the last 12 months, Kairos Pharma, Ltd. had revenue of 0 and earned -5.45M in profits. Earnings per share was -2.10.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -5.57M
- Pretax Income
- -5.45M
- Net Income
- -5.45M
- EBITDA
- -5.29M
- Earnings Per Share (EPS)
- -2.10
Cash Flow
In the last 12 months, operating cash flow was -4.11M and capital expenditures 0, giving a free cash flow of -4.11M billion.
- Operating Cash Flow
- -4.11M
- Free Cash Flow
- -4.11M
- Free Cash Flow per Share
- -1.23
Dividends & Yields
Kairos Pharma, Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -267.71%
- Earnings Yield
- -420.69%
Stock Price Statistics
- Beta
- 1.41
- 52-Week Price Change
- -91.82%
- 50-Day Moving Average
- 1.08
- 200-Day Moving Average
- 2.76
- Relative Strength Index (RSI)
- 27.35
- Average Volume (3m)
- 364.48K
Financial Position
Kairos Pharma, Ltd. as a current ratio of 27.07, with Debt / Equity ratio of 0.00%
- Current Ratio
- 27.07
- Quick Ratio
- 27.07
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.85
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Kairos Pharma, Ltd. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Kairos Pharma, Ltd. EV to EBITDA ratio is 0.25, with an EV/FCF ratio of 0.39.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.25
- EV to Free Cash Flow
- 0.39
- EV to Operating Cash Flow
- 0.39
Balance Sheet
Kairos Pharma, Ltd. has $3.13M in cash and marketable securities with $0.00 in debt, giving a net cash position of $3.13M billion.
- Cash & Marketable Securities
- $3.13M
- Total Debt
- $0.00
- Net Cash
- $3.13M
- Net Cash Per Share
- $0.92
- Tangible Book Value Per Share
- $1.16
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Kairos Pharma, Ltd. is $12.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $12.00
- Price Target Upside
- 2549.01% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 30.88%

